2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1350

Ultrasound Detected Tenosynovitis in Rheumatoid Arthritis Patients in Clinical Remission
Abstract Number: 1373

Ultrasound of Subtalar Joint Synovitis in Patients with Rheumatoid Arthritis: Results of an Omeract Reliability Exercise Using Consensual Definitions
Abstract Number: 1391

Ultrasound Response to Tocilizumab in Surgically Replaced Joints and Surgically Operated Joint Areas of Rheumatoid Arthritis Patients
Abstract Number: 2943

Ultrasound Scoring of One Parotid and One Submandibular Gland in Primary Sjogren’s Syndrome – Further Increasing Feasibility in Outpatient Clinics
Abstract Number: 669

Unbiased Screening of Urinary Protein Biomarkers for Glomerular Filtration Rate Normalization
Abstract Number: 2772

Unbound IL-18 Distinguishes Human Macrophage Activation Syndrome from Familial Hemophagocytic Lymphohistiocytosis and Affects Innate Versus Adaptive Murine Lymphocytes Differently
Abstract Number: 1119

Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US
Abstract Number: 1241

Understanding Differences in Patient Definitions of RA Flares Using Omeract Core Domains
Abstract Number: 341

Understanding Perceptions and Experience of Gout through Linguistic Analysis of Online Search Activities
Abstract Number: 2725

Understanding Vasculitis Patients’ Ability to Work with Numbers
Abstract Number: 156

Unexpectedly High Prevalence of Immunoglobulin Deficiency in Fibromyalgia – II
Abstract Number: 1901

Unfavorable Body Composition Already at the Onset of Clinical Arthritis
Abstract Number: 1697

Unique Characteristics of Scleroderma Among African Americans: A Population Based Study
Abstract Number: 1336

Unique Role for miR429 in RA and Acute Model of Arthritis
Abstract Number: 829

Unraveling Race and Social Context in Understanding Disparities in Lupus Mortality in the United States

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].